Cohance Lifesciences Stock Plummets to New 52-Week Low at Rs. 609.1

Cohance Lifesciences has reached a significant milestone by hitting a new 52-week low of Rs.609.1 today, November 17, 2025. This marks a notable decline for the small-cap pharmaceutical and biotechnology company, which has seen its stock price fall by 28.35% over the past 13 consecutive trading days. In terms of performance, Cohance Lifesciences has underperformed its sector by 0.48% today, reflecting broader market trends. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a sustained downward trajectory. Over the past year, the stock has generated a return of -52.18%, contrasting sharply with the Sensex's performance of 9.21% during the same period. The company's financial metrics reveal a challenging landscape, with operating profit growth averaging just 4.15% annually over the last five years. Additionally, recent quarterly results have shown declines in key performance indicators, including a 42.4% drop in profit before tax compared to previous quarters. With 100% of promoter shares pledged, the stock faces additional pressure in a declining market.